Periorbital Infections

Back

Background

Periorbital infections consist of a group of infections that can be broadly classified into 2 distinct groups. One group consists of infections of the dermis and associated tissues around the eyes. The other group consists of infections of the lacrimal system. (See Presentation and Workup.)

Periorbital cellulitis

Infections of the superficial skin around the eyes are called periorbital, or preseptal, cellulitis. These infections are limited to the area anterior to the orbital septum. Periorbital cellulitis is predominantly, although not exclusively, a pediatric disease (see the image below). (See Presentation, Workup, Treatment, and Medication.)[1, 2]



View Image

Periorbital cellulitis. This image shows an 8-year-old patient who presented with unilateral eyelid swelling and erythema.

Periorbital cellulitis represents the first of the 5 nonprogressive types of orbital infections. These are classified as follows[3] :

Lacrimal system infections

Infections of the lacrimal system are classified based on the location of the infection; they include the following (see Presentation, Workup, Treatment, and Medication):

Patient education

For patient education information, see Cellulitis. A blepharitis fact sheet is available for purchase from the American Academy of Ophthalmology.[6]

Anatomy

Orbital septum

The orbital septum is a fibrous membrane that extends from the periosteum of the orbit as the arcus marginalis and lies just deep to the orbicularis oculi muscle.

In the upper lids, the septum fuses with the levator aponeurosis. In the lower lids, the septum fuses with the capsulopalpebral fascia.[7] The orbital septum acts as a physical barrier to the spread of infection.

Note the anatomical drawings below.



View Image

Upper eyelid anatomy.



View Image

Lower eyelid anatomy.

Lacrimal system

The lacrimal system includes the structures involved in the production and drainage of tears. The lacrimal gland is located in the lateral upper lid margin. It produces about 10 mL of secretions per day.

In the process of blinking, the eyes close from the lateral edge to the medial edge, pushing the tear film across the surface of the eye. Most of the tear volume is lost through evaporation. A small portion is drained from the lacrimal lake, located at the inner canthus, through the puncta and into the superior and inferior canaliculi. Tears then flow into the common canaliculus and lacrimal sac.

The lacrimal duct, which lies within the bone, connects the lacrimal sac with the eventual site of egress, the inferior meatus of the nose.[7]

Note the anatomical drawings below.



View Image

Eye and lacrimal duct, anterior view.

Etiology

Periorbital cellulitis

Periorbital cellulitis can occur by several mechanisms, including the following[2, 8] :

Infectious organisms

When associated with trauma, periorbital cellulitis can be caused by the following bacterial species:

In the absence of trauma, periorbital cellulitis can be caused by the following microbes:

Other unusual causes of periorbital cellulitis include the following:

Blepharitis

Anterior blepharitis is usually secondary to infection or seborrheic in nature, or else it is a combination of both. If the pilosebaceous glands of Zeiss and Moll become infected, an abscess may occur. This abscess is known as an external hordeolum, or stye.[22] Cell-mediated immunologic mechanisms have been implicated in the development of chronic blepharitis.[23, 24]

Posterior blepharitis is caused by Meibomian gland dysfunction. The Meibomian gland secretes the oily layer of the tear film. This oily layer is responsible for preventing excessive evaporation of the aqueous layer of the tear film. If the secretions become inspissated, causing plugging of the gland, a chalazion may develop. A chalazion is a noninfectious, granulomatous reaction. If there is infection secondary to plugging, an internal hordeolum develops.[25]

The use of eye makeup, especially eyeliner, can cause acute exacerbations of blepharitis by plugging the glands.[26]

Anterior blepharitis

Causative organisms in anterior blepharitis include the following:

Posterior blepharitis

Etiologic characteristics of posterior blepharitis include the following:

Dacryoadenitis

Dacryoadenitis is caused by local infection of the lacrimal gland by bacteria or viruses. Chronic dacryoadenitis associated with inflammation and swelling of the salivary glands of unknown origin is called Mikulicz disease. When associated with other entities such as tuberculosis, sarcoidosis, or lymphoma, it is termed Mikulicz syndrome. This was previously considered a subtype of Sjögren syndrome, although now differences between the 2 entities have been determined.[33]

Bacteria

Dacryoadenitis is most often caused by gram-positive cocci, usually staphylococci. It may also be caused by S pneumoniae.

Viruses

Prior to increased immunization rates, the mumps virus was most often implicated in the development of dacryoadenitis. Now, the Epstein-Barr virus is most often associated with chronic dacryoadenitis.[34]

Dacryocystitis

Dacryocystitis is caused by inflammation of the lacrimal sac; this usually occurs in the setting of obstruction of the lacrimal apparatus. The obstruction may be congenital or secondary to infection, tumor, or trauma.[7]

Infectious causes include gram-positive isolates (Staphylococcus and Streptococcus species), in 71-78% of cases, and gram-negative isolates, in 22-29% of cases.[35, 36] Rarely, dacryocystitis may result from mucormycosis.[37]

Canaliculitis

Canaliculitis is caused by infection of the canaliculi; often, it is chronic. The disorder may also be iatrogenic, occurring after the use of instrumentation or the placement of silicone plugs in the treatment of dry eyes.[38]

It is classically taught that the most common pathogens of canaliculitis are Actinomyces israelii and Nocardia (formerly known as Streptothrix) species.[5, 39]

Case reviews, however, have shown mixed flora associated with infection. Species isolated include Staphylococcus species, Escherichia coli, Haemophilus species, Pseudomonas aeruginosa, Klebsiella oxytocia,[40] Arcanobacterium (previously Corynebacterium) haemolyticum,[41] and M chelonae.[42]

Prognosis

Prognoses in periorbital infections are as follows:

Complications

Periorbital cellulitis

Complications of periorbital cellulitis include the following:

Blepharitis

Complications of blepharitis include the following:

Dacryocystitis

Dacryocystitis may be associated with periorbital cellulitis. Rarely, it may be associated with orbital cellulitis or abscess formation. This is usually prevented by the orbital septum, which surrounds the lacrimal sac.[45]

Complications may occur during a dacryocystorhinostomy, including hemorrhage, infection, and cerebrospinal fluid (CSF) leakage.

Canaliculitis

Epiphora may result from failure of tear film to appropriately drain through the lacrimal system.

Pathophysiology

S aureus, Staphylococcus epidermidis, and S pyogenes account for approximately 75% of pediatrics periorbital infections. Staphylococcus and Streptococcus are the most two common pathogens responsible for pediatric orbital cellulitis.[46]

Epidemiology

Periorbital cellulitis is primarily a pediatric disease, occurring mostly in children younger than 5 years. Periorbital cellulitis is almost three times more common than orbital cellulitis.

While orbital cellulitis is more common in the pediatric population, it can affect all age groups. In one retrospective analysis, the average age of affected patients was 6.8 years (ranging from age 1 week to 16 years).[47] Worldwide, orbital cellulitis occurs more often in winter. It is associated with upper respiratory tract infections, and most cases have a unilateral presentation.[48, 49]

Periorbital cellulitis has no sexual predilection. Orbital infections have a male-to-female ratio of 2:1. 

History

Periorbital cellulitis

Patient history may include the following:

Blepharitis

Characteristics include the following:

Dacryoadenitis

The disease is characterized by swelling of upper lateral eyelid and scleral injection. If dacryoadenitis is caused by a viral infection, the area is modestly tender. Bacterial causes result in more severe tenderness.[25]

Dacryocystitis

A history of chronic conjunctivitis or recent upper respiratory infection may be present. Other signs include the following:

Canaliculitis

Patient history may include the following:

Physical Examination

Periorbital cellulitis

Examination may reveal the following:

Blepharitis

Anterior blepharitis

Signs of anterior blepharitis include the following:

Posterior blepharitis

Signs of posterior blepharitis include the following:

Dacryoadenitis

The signs of dacryoadenitis include the following:

Dacryocystitis

Erythema, swelling, warmth, and tenderness may be noted over the lacrimal sac at the inferior aspect of the medial canthus. Application of pressure to the area overlying the lacrimal sac may cause expression of purulent material from the lacrimal puncta. (See the image below.)



View Image

Acute dacryocystitis.

Canaliculitis

Signs of canaliculitis include the following:

Approach Considerations

Laboratory studies

The following laboratory studies may be performed in patients with periorbital infection:

Lumbar puncture

If a patient with periorbital cellulitis is toxic appearing, a lumbar puncture may be indicated to exclude meningeal infection.

Biopsy

Biopsy may be indicated in the following cases:

Schirmer test

The Schirmer test is used to assess tear production. Results are nonspecific as to the etiology of dry eyes.

Imaging Studies

Periorbital cellulitis

Contrast-enhanced computed tomography (CT) scanning of the orbits should be performed if there is concern for orbital and subperiosteal involvement and cavernous sinus thrombosis. CT scanning also helps to distinguish sinusitis as a cause.

Indications for CT scanning include the following[61] :

CT scanning will show lid edema but no proptosis or "streaking" of the orbital fat, which lies posterior to the orbital septum.

Patients whose condition fails to improve after 24-36 hours of appropriate antimicrobial therapy should also have CT performed.[61]

In an attempt to better target patients needing emergent CT scanning, Rudloe et al presented a recursive partitioning model for identification of predictors of intraorbital or intracranial abscess, for use in pediatric patients with signs or symptoms of periorbital infection.[62]

Results of the study confirmed that patients with proptosis and/or pain or limitation of extraocular movements are at high risk for intraorbital abscess, though many patients with abscess do not have these predictors. The investigators also concluded, based on multivariate analysis, that the following findings can identify patients at significant risk when the obvious predictors are not present:

Magnetic resonance imaging (MRI) with MR venography is the study of choice to rule out cavernous sinus thrombosis, although the initial evaluation is often done with CT venography.[63]

Canaliculitis

20-MHz ultrasonography can be used to detect sulfur granules within the canaliculi.[64]

Jones Dye Test

The Jones dye test is used to assess patency of the lacrimal drainage system. In the first part of the test, a drop of fluorescein is placed in the conjunctival cul-de-sac. After 5 minutes, the nose is examined for the presence of dye. If no dye is present, an obstruction is present and the second part of the test is performed.

In the second part of the test, a cannula is placed into the lacrimal sac, which is then washed with saline. If no fluorescein is noted, the dye is obstructed in the upper (canalicular) portion of the system. If dye is present, then the obstruction is in the lower (sac, duct) portion.[65]

Other Tests

The main role of MRI is the evaluation of intracranial complications such as cerebritis or cavernous sinus thrombosis. 

Approach Considerations

Periorbital cellulitis

In adult patients who are nontoxic and can be assured of appropriate follow-up, treatment can be administered with oral antibiotics on an outpatient basis. No evidence suggests that intravenous antibiotics are superior to oral antibiotics in the management of simple periorbital cellulitis in terms of faster recovery or prevention of complications.[66] The antibiotic should offer coverage of Staphylococcus and Streptococcus.[43]

Patients who undergo outpatient treatment should be seen daily to ensure clinical improvement. The length of antibiotic treatment is 7-10 days; however, it should be guided by symptom resolution. Clinical improvement should be evident within 1-2 days after initiation of antibiotics.[67] Nasal decongestants may be used for the short term to reduce mucosal edema.[61]

Inpatient care, with administration of intravenous antibiotics, is indicated for the treatment of periorbital cellulitis in most pediatric patients. Full septic evaluation must be considered if the patient is toxic-appearing or has any signs of nervous system involvement (eg, headache, vomiting, seizure, cranial nerve deficits).[43] Once clinical improvement is noted, the patient should be switched to oral antibiotics. 

A Clinical Severity Index has been established for periorbital cellulitis in children. It uses systemic features of patient interaction and fever, as well as local features of location, erythema, extent of eye opening, and pain and tenderness.[68]

Patients with an infection of odontogenic origin may have improved outcomes with early definitive treatment of dentition.[69]

Assessment considerations

A study by Upile and colleagues indicated that in most cases, daily assessment of hospital patients with periorbital cellulitis only infrequently requires an otorhinolaryngologist, despite concerns regarding possible intracranial and orbital complications in these patients. Using a retrospective analysis of 213 case notes from a tertiary children’s hospital, the investigators found that most patients were successfully managed by pediatricians and ophthalmologists.

Upile et al concluded that in patients with periorbital cellulitis, otorhinolaryngologic assessment is required only after first-line treatment of the disease has failed.[70]

Blepharitis

The treatment of blepharitis, regardless of etiology, begins with eyelid hygiene. The patient should be instructed to wash the lids with a nonirritating baby shampoo or a commercially prepared lid scrubbing solution and to use warm compresses for 15 minutes at a time, 3 or 4 times a day. Collarettes at the base of the lashes can be gently removed using a cotton-tipped applicator.

If the blepharitis is suspected of being infectious, a topical antibiotic such as bacitracin, erythromycin,[71] or levofloxacin[72] should be prescribed. The frequency and duration of treatment should be determined based on the severity of the disease process.[73] Usually, the topical antibiotic is applied 2-4 times daily for 2 weeks.[74]

Posterior blepharitis may be treated with an oral tetracycline; this medication decreases lipase production in staphylococci, preventing plugging of Meibomian glands. Such therapy is limited to patients older than 8 years due to the risk of tooth enamel discoloration.[73] Alternative treatment with topical azithromycin is effective and safe.[75]

Other medications used to treat blepharitis include the following[76] :

If blepharitis is caused by infestation with the mite D folliculorum, treatment with weekly lid scrubs with 50% tea tree oil and daily scrubs with tea tree shampoo for a minimum of 6 weeks has been shown to decrease mite load and improve inflammatory responses.[79]

Phthiriasis palpebrarum has been treated with twice-daily application of petrolatum for 7-10 days. This therapy fails to kill ova, however, and infection may be persistent. An alternative therapy has been proposed using pilocarpine 4% gel twice daily for 10 days. The mechanism of action of this therapy is not well understood.[80] In addition, removal of the nits and lice can be accomplished with forceps.

Dacryoadenitis

Treatment of acute dacryoadenitis is largely supportive because the disease is usually self-limiting. Use warm compresses and nonsteroidal anti-inflammatory drugs (NSAIDs).

If the etiology is bacterial, antibiotic treatment with a first-generation cephalosporin should be started. If the disease has been caused by Epstein-Barr virus, steroids have been shown to improve the clinical course.[81] For chronic dacryoadenitis, treat the underlying condition.

Dacryocystitis

Treat this disorder with oral antibiotics such as amoxicillin-clavulanic acid or dicloxacillin. In pediatric patients, the obstruction usually resolves by age 9-12 months. Many pediatric ophthalmologists will wait until after this age to probe the ducts to free the obstruction.[82]

Dacryocystorhinostomy is the surgical procedure of choice. This operation allows for the bypassing of the lacrimal duct apparatus as long as the canalicular apparatus is intact.[83]

Punctal dilation and nasolacrimal irrigation is contraindicated in the acute stage due to the increased risk of periorbital cellulitis.

Canaliculitis

Treatments for this disorder include the following:

Consultations

Consider consultation with an ophthalmologist, otolaryngologist, or neurosurgeon for any patient who may have orbital involvement.

Most cases of lacrimal system infection can be managed conservatively. Consultation with an ophthalmologist or otolaryngologist is indicated if the condition is not resolved within 24-48 hours.

Complications

Complications of periorbital cellulitis include the following:

Medication Summary

Antibiotics are used in the treatment of periorbital infections, with the specific disorder dictating whether topical, oral, or intravenous agents are administered. As previously stated, for example, treatment of orbital cellulitis commonly starts with intravenous antibiotics in pediatric patients and with oral antibiotics in adults.

Topical antibiotics such as bacitracin, erythromycin, and levofloxacin are used in cases of blepharitis, if the disease is thought to be infectious.

Bacteria frequently associated with periorbital infections include species of Streptococcus and Staphylococcus.

Cephalexin (Keflex)

Clinical Context:  Cephalexin is a first-generation cephalosporin that inhibits bacterial replication by inhibiting bacterial cell wall synthesis. It is bactericidal and effective against rapidly growing organisms forming cell walls. Resistance occurs through alteration of penicillin-binding proteins.

Cephalexin is effective for the treatment of infections caused by streptococci or staphylococci, including penicillinase-producing staphylococci. It may be used to initiate therapy when streptococcal or staphylococcal infection is suspected. The drug is used orally when outpatient management is indicated.

Cephalexin has a half-life of 50-80 minutes. Only 10% is protein bound and more than 90% is recovered unchanged in urine.

Ampicillin and sulbactam (Unasyn)

Clinical Context:  This agent features ampicillin combined with a beta-lactamase inhibitor. It interferes with bacterial cell wall synthesis during active replication, causing bactericidal activity against susceptible organisms. The ampicillin-sulbactam combination provides useful coverage for most organisms associated with dacryocystitis.

Clindamycin (Cleocin)

Clinical Context:  This agent is a semisynthetic antibiotic produced by 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound, lincomycin. Clindamycin inhibits bacterial growth, possibly by blocking dissociation of peptidyl transfer ribonucleic acid (tRNA) from ribosomes, causing RNA-dependent protein synthesis to arrest. The drug is widely distributed in the body without penetration of the central nervous system (CNS). It is protein bound and excreted by the liver and kidneys.

Clindamycin is used for the treatment of serious skin and soft tissue staphylococcal infections. It is also effective against aerobic and anaerobic streptococci (except enterococci). As an alternative to sulfonamides, clindamycin may be beneficial when used with pyrimethamine in acute treatment of CNS toxoplasmosis in patients with acquired immunodeficiency syndrome (AIDS).

Trimethoprim/sulfamethoxazole (Bactrim DS, Septra DS)

Clinical Context:  Trimethoprim/sulfamethoxazole inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid. The antibacterial activity of trimethoprim/sulfamethoxazole includes common urinary tract pathogens, except Pseudomonas aeruginosa.

Doxycycline (Doryx, Doxy 100, Periostat, Oraxyl, Vibramycin)

Clinical Context:  Doxycycline is a broad-spectrum, synthetically derived, bacteriostatic antibiotic in the tetracycline class. It is almost completely absorbed, concentrates in bile, and is excreted in urine and feces as a biologically active metabolite in high concentrations.

Doxycycline inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. It may block the dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest.

Vancomycin

Clinical Context:  Vancomycin is a potent antibiotic directed against gram-positive organisms and active against Enterococcus species. It is useful in the treatment of septicemia and skin structure infections and is indicated for patients who cannot receive, or have failed to respond to, penicillins and cephalosporins or who have infections with resistant staphylococci. For abdominal penetrating injuries, vancomycin is combined with an agent active against enteric flora and/or anaerobes.

To avoid toxicity, the current recommendation is to assay vancomycin trough levels after the third dose, drawn 0.5 hour prior to the next dosing. Use creatinine clearance to adjust the dose in patients diagnosed with renal impairment.

Vancomycin is used in conjunction with gentamicin for prophylaxis in penicillin-allergic patients undergoing gastrointestinal or genitourinary procedures.

Cefuroxime (Ceftin, Zinacef)

Clinical Context:  Cefuroxime is a second-generation cephalosporin that maintains the gram-positive activity found in first-generation cephalosporins and adds activity against Proteus mirabilis, H influenzae, E coli, K pneumoniae, and M catarrhalis.

The condition of the patient, the severity of infection, and the susceptibility of the microorganism determine the proper dose and route of administration.

Nafcillin

Clinical Context:  Nafcillin is used in the initial therapy for suspected penicillin G-resistant streptococcal or staphylococcal infections. Parenteral therapy should be used initially in severe infections, with a change made to oral treatment as the condition warrants.

Because of thrombophlebitis, particularly in elderly persons, nafcillin should be administered parenterally only for a short term (1-2 days); change to an oral antibiotic should be made as clinically indicated.

Amoxicillin and clavulanic acid (Augmentin)

Clinical Context:  This drug combination treats bacteria resistant to beta-lactam antibiotics. For children older than 3 months, base the dosing protocol on amoxicillin content. Because of different amoxicillin/clavulanic acid ratios in the 250 mg tablet (250/125) versus the 250 mg chewable tablet (250/62.5), do not use the 250 mg tablet until the child weighs more than 40 kg.

Cefaclor

Clinical Context:  Cefaclor is a second-generation cephalosporin indicated for infections caused by susceptible gram-positive cocci and gram-negative rods. Determine the proper dosage and route based on the patient's condition, the infection's severity, and the causative organism's susceptibility.

Tetracycline

Clinical Context:  Tetracycline treats gram-positive and gram-negative organisms as well as mycoplasmal, chlamydial, and rickettsial infections. It inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunits.

Bacitracin (Baciguent)

Clinical Context:  This agent prevents the transfer of mucopeptides into the growing cell wall, inhibiting bacterial growth.

Erythromycin ophthalmic (Ilotycin)

Clinical Context:  This agent is a macrolide antibiotic that binds to the 50S ribosomal subunit, blocking dissociation of peptidyl tRNA from the ribosomes and causing RNA-dependent protein synthesis to arrest. It does not affect nucleic acid synthesis.

Erythromycin ophthalmic is indicated for infections caused by susceptible strains of microorganisms and for the prevention of corneal and conjunctival infections.

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

What are periorbital infections?What is periorbital cellulitis?How is periorbital cellulitis classified?How are periorbital infections of the lacrimal system classified?What is the anatomy of orbital septum relevant to periorbital infections?What is the anatomy of lacrimal system relevant to periorbital infections?What causes canaliculitis?What causes periorbital cellulitis?What causes periorbital cellulitis following trauma?What causes periorbital cellulitis in the absence of trauma?What are other unusual causes of periorbital cellulitis?What causes blepharitis?What causes anterior blepharitis?What causes posterior blepharitis?What causes dacryoadenitis?What causes dacryocystitis?What is the prognosis of periorbital infections?What are the possible complications of periorbital cellulitis?What are the possible complications of blepharitis?What is the prognosis of dacryocystitis?What is the prognosis of canaliculitis?What is the pathophysiology of periorbital infections?What is the prevalence of periorbital infections?Which clinical history findings are characteristic of periorbital cellulitis?Which clinical history findings are characteristic of blepharitis?Which clinical history findings are characteristic of dacryoadenitis?Which clinical history findings are characteristic of dacryocystitis?Which clinical history findings are characteristic of canaliculitis?Which physical findings are characteristic of periorbital cellulitis?Which physical findings are characteristic of anterior blepharitis?Which physical findings are characteristic of posterior blepharitis?Which physical findings are characteristic of dacryoadenitis?Which physical findings are characteristic of dacryocystitis?Which physical findings are characteristic of canaliculitis?Which conditions should be included in the differential diagnosis of periorbital cellulitis?Which conditions should be included in the differential diagnosis of blepharitis?Which conditions should be included in the differential diagnosis of dacryoadenitis?Which conditions should be included in the differential diagnosis of canaliculitis?What are the differential diagnoses for Periorbital Infections?What is the role of lab testing in the workup of periorbital infections?What is the role of lumbar puncture in the workup of periorbital infections?What is the role of biopsy in the diagnosis of periorbital infections?What is the role of Schirmer test in the diagnosis of periorbital infections?What is the role of CT scanning in the diagnosis of periorbital infections?What is the role of MRI in the diagnosis of periorbital infections?What is the role of ultrasonography in the workup of preorbital infections?What is the role of Jones dye test in the diagnosis of periorbital infections?How are intracranial complications of periorbital infections evaluated?How is periorbital cellulitis treated?How is blepharitis treated?How is dacryoadenitis treated?How is dacryocystitis treated?What are treatments for canaliculitis treated?Which specialist consultations are beneficial to patients with periorbital infections?What are the possible complications of periorbital cellulitis?Which medications are used in the treatment of periorbital infections?Which medications in the drug class Antibiotics, Other are used in the treatment of Periorbital Infections?

Author

Bobak Zonnoor , MD, Resident Physician, Department of Emergency Medicine, SUNY Downstate Medical Center, Kings County Hospital

Disclosure: Nothing to disclose.

Coauthor(s)

Elizabeth Fiedler, MD, Clinical Instructor, Department of Emergency Medicine, Montefiore Medical Center-Weiler Division

Disclosure: Nothing to disclose.

Richard H Sinert, DO, Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Vice-Chair in Charge of Research, Department of Emergency Medicine, Kings County Hospital Center

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Pfizer Pharmaceutical<br/>Received research grant from: National Institutes Health.

Zach Kassutto, MD, FAAP, Director, Pediatric Emergency Medicine, Capital Health System; Associate Professor of Pediatrics and Emergency Medicine, Drexel University College of Medicine; Attending Physician, St Christopher's Hospital for Children

Disclosure: Nothing to disclose.

Chief Editor

Gil Z Shlamovitz, MD, FACEP, Associate Professor of Clinical Emergency Medicine, Keck School of Medicine of the University of Southern California; Chief Medical Information Officer, Keck Medicine of USC

Disclosure: Nothing to disclose.

Additional Contributors

R Gentry Wilkerson, MD, FACEP, FAAEM, Assistant Professor, Coordinator for Research, Department of Emergency Medicine, University of Maryland School of Medicine

Disclosure: Nothing to disclose.

Robert E O'Connor, MD, MPH, Professor and Chair, Department of Emergency Medicine, University of Virginia Health System

Disclosure: Nothing to disclose.

Acknowledgements

Edmond A Hooker II, MD, DrPH, FAAEM Assistant Professor, Department of Emergency Medicine, University of Cincinnati College of Medicine

Edmond A Hooker II, MD, DrPH, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American Public Health Association, Society for Academic Emergency Medicine, and Southern Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References

  1. Givner LB, Mason EO Jr, Barson WJ, et al. Pneumococcal facial cellulitis in children. Pediatrics. 2000 Nov. 106(5):E61. [View Abstract]
  2. Moubayed SP, Vu TT, Quach C, Daniel SJ. Periorbital cellulitis in the pediatric population: clinical features and management of 117 cases. J Otolaryngol Head Neck Surg. 2011 Jun. 40(3):266-70. [View Abstract]
  3. Chandler JR, Langenbrunner DJ, Stevens ER. The pathogenesis of orbital complications in acute sinusitis. Laryngoscope. 1970 Sep. 80(9):1414-28. [View Abstract]
  4. Chin RL. Emergency Management of Infectious Diseases. Cambridge University Press; 2008. 151.
  5. Gershon. Krugman's Infectious Diseases of Children. 11th ed. 2004. (MD Consult) [pg 163-4].
  6. American Academy of Ophthalmology. Blepharitis Fact Sheet. Accessed December 3, 2009.
  7. Yanoff. Ophthalmology [MD Consult]. 2nd ed. 2004. chap 82, 98.
  8. Givner LB. Periorbital versus orbital cellulitis. Pediatr Infect Dis J. 2002 Dec. 21(12):1157-8. [View Abstract]
  9. Brook I. Microbiology of acute sinusitis of odontogenic origin presenting with periorbital cellulitis in children. Ann Otol Rhinol Laryngol. 2007 May. 116(5):386-8. [View Abstract]
  10. Charalampidou S, Connell P, Fennell J, et al. Preseptal cellulitis caused by community acquired methicillin resistant Staphylococcus aureus (CAMRSA). Br J Ophthalmol. 2007 Dec. 91(12):1723-4. [View Abstract]
  11. Ambati BK, Ambati J, Azar N, et al. Periorbital and orbital cellulitis before and after the advent of Haemophilus influenzae type B vaccination. Ophthalmology. 2000 Aug. 107(8):1450-3. [View Abstract]
  12. Donahue SP, Schwartz G. Preseptal and orbital cellulitis in childhood. A changing microbiologic spectrum. Ophthalmology. 1998 Oct. 105(10):1902-5; discussion 1905-6. [View Abstract]
  13. Schwartz GR, Wright SW. Changing bacteriology of periorbital cellulitis. Ann Emerg Med. 1996 Dec. 28(6):617-20. [View Abstract]
  14. Green JA, Lim J, Barkham T. Neisseria gonorrhoeae: a rare cause of preseptal cellulitis?. Int J STD AIDS. 2006 Feb. 17(2):137-8. [View Abstract]
  15. Chand DV, Hoyen CK, Leonard EG, et al. First reported case of Neisseria meningitidis periorbital cellulitis associated with meningitis. Pediatrics. 2005 Dec. 116(6):e874-5. [View Abstract]
  16. Porras MC, Martínez VC, Ruiz IM, et al. Acute cellulitis: an unusual manifestation of meningococcal disease. Scand J Infect Dis. 2001. 33(1):56-9. [View Abstract]
  17. Lewis FM, Chernak E, Goldman E, et al. Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg Infect Dis. 2006 Jan. 12(1):134-7. [View Abstract]
  18. Fillmore GL, Ward TP, Bower KS, et al. Ocular complications in the Department of Defense Smallpox Vaccination Program. Ophthalmology. 2004 Nov. 111(11):2086-93. [View Abstract]
  19. Raina UK, Jain S, Monga S, et al. Tubercular preseptal cellulitis in children: a presenting feature of underlying systemic tuberculosis. Ophthalmology. 2004 Feb. 111(2):291-6. [View Abstract]
  20. Artac H, Silahli M, Keles S, et al. A rare cause of preseptal cellulitis: anthrax. Pediatr Dermatol. 2007 May-Jun. 24(3):330-1. [View Abstract]
  21. Kohli V, Gaur S, Deen M, Engel M, Shah K. Orbital cysticercosis presenting as recurrent periorbital cellulitis in a four-year-old child. Pediatr Infect Dis J. 2010 May. 29(5):481. [View Abstract]
  22. Noble. Textbook of Primary Care Medicine [MD Consult]. 3rd ed. 2001. 1693.
  23. Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther. 2006 Feb. 22(1):47-53. [View Abstract]
  24. Lee SH, Oh DH, Jung JY, Kim JC, Jeon CO. Comparative ocular microbial communities in humans with and without blepharitis. Invest Ophthalmol Vis Sci. 2012 Aug 15. 53(9):5585-93. [View Abstract]
  25. Wald ER. Periorbital and orbital infections. Infect Dis Clin North Am. 2007 Jun. 21(2):393-408, vi. [View Abstract]
  26. American Academy of Ophthalmology. Preferred Practice Patterns: Blepharitis. Accessed December 3, 2009.
  27. Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol. 2008 Apr. 43(2):170-9. [View Abstract]
  28. Sacca SC, Pascotto A, Venturino GM, et al. Prevalence and treatment of Helicobacter pylori in patients with blepharitis. Invest Ophthalmol Vis Sci. 2006 Feb. 47(2):501-8. [View Abstract]
  29. Kheirkhah A, Casas V, Li W, et al. Corneal manifestations of ocular demodex infestation. Am J Ophthalmol. 2007 May. 143(5):743-749. [View Abstract]
  30. Thappa DM, Karthikeyan K, Jeevankumar B. Phthiriasis palpebrarum. Postgrad Med J. 2003 Feb. 79(928):102. [View Abstract]
  31. Mathers WD, Shields WJ, Sachdev MS, Petroll WM, Jester JV. Meibomian gland dysfunction in chronic blepharitis. Cornea. 1991 Jul. 10(4):277-85. [View Abstract]
  32. Seal DV, McGill JI, Jacobs P, Liakos GM, Goulding NJ. Microbial and immunological investigations of chronic non-ulcerative blepharitis and meibomianitis. Br J Ophthalmol. 1985 Aug. 69(8):604-11. [View Abstract]
  33. Lee S, Tsirbas A, McCann JD, et al. Mikulicz's disease: a new perspective and literature review. Eur J Ophthalmol. 2006 Mar-Apr. 16(2):199-203. [View Abstract]
  34. Rhem MN, Wilhelmus KR, Jones DB. Epstein-Barr virus dacryoadenitis. Am J Ophthalmol. 2000 Mar. 129(3):372-5. [View Abstract]
  35. Mills DM, Bodman MG, Meyer DR, et al. The microbiologic spectrum of dacryocystitis: a national study of acute versus chronic infection. Ophthal Plast Reconstr Surg. 2007 Jul-Aug. 23(4):302-6. [View Abstract]
  36. Bharathi MJ, Ramakrishnan R, Maneksha V, Shivakumar C, Nithya V, Mittal S. Comparative bacteriology of acute and chronic dacryocystitis. Eye (Lond). 2008 Jul. 22(7):953-60. [View Abstract]
  37. Kapur R, Aakalu VK, August CZ, Weiss RA. Mucormycosis infection of the lacrimal sac. Ophthal Plast Reconstr Surg. 2009 Nov-Dec. 25(6):494-6. [View Abstract]
  38. Lee J, Flanagan JC. Complications associated with silicone intracanalicular plugs. Ophthal Plast Reconstr Surg. 2001 Nov. 17(6):465-9. [View Abstract]
  39. Zaldívar RA, Bradley EA. Primary canaliculitis. Ophthal Plast Reconstr Surg. 2009 Nov-Dec. 25(6):481-4. [View Abstract]
  40. Anand S, Hollingworth K, Kumar V, et al. Canaliculitis: the incidence of long-term epiphora following canaliculotomy. Orbit. 2004 Mar. 23(1):19-26. [View Abstract]
  41. Varma D, Chang B, Musaad S. A case series on chronic canaliculitis. Orbit. 2005 Mar. 24(1):11-4. [View Abstract]
  42. Moscato EE, Sires BS. Atypical canaliculitis. Ophthal Plast Reconstr Surg. 2008 Jan-Feb. 24(1):54-5. [View Abstract]
  43. Hauser A, Fogarasi S. Periorbital and orbital cellulitis. Pediatr Rev. 2010 Jun. 31 (6):242-9. [View Abstract]
  44. Lazzeri D, Lazzeri S, Figus M, Tascini C, Bocci G, Colizzi L, et al. Periorbital Necrotizing Fasciitis. Br J Ophthalmol. 2009 Nov 5. [View Abstract]
  45. Ataullah S, Sloan B. Acute dacryocystitis presenting as an orbital abscess. Clin Experiment Ophthalmol. 2002 Feb. 30(1):44-6. [View Abstract]
  46. Botting AM, McIntosh D, Mahadevan M. Paediatric pre- and post-septal peri-orbital infections are different diseases. A retrospective review of 262 cases. Int J Pediatr Otorhinolaryngol. 2008 Mar. 72 (3):377-83. [View Abstract]
  47. McKinley SH, Yen MT, Miller AM, Yen KG. Microbiology of pediatric orbital cellulitis. Am J Ophthalmol. 2007 Oct. 144 (4):497-501. [View Abstract]
  48. Liu IT, Kao SC, Wang AG, Tsai CC, Liang CK, Hsu WM. Preseptal and orbital cellulitis: a 10-year review of hospitalized patients. J Chin Med Assoc. 2006 Sep. 69 (9):415-22. [View Abstract]
  49. Ho CF, Huang YC, Wang CJ, Chiu CH, Lin TY. Clinical analysis of computed tomography-staged orbital cellulitis in children. J Microbiol Immunol Infect. 2007 Dec. 40 (6):518-24. [View Abstract]
  50. Friedlaender MH. Blepharitis, allergy, and dry eye: lumpers and splitters. Ann Ophthalmol (Skokie). 2006 Spring. 38(1):4-5. [View Abstract]
  51. Thirumoorthi MC, Asmar BI, Dajani AS. Violaceous discoloration in pneumococcal cellulitis. Pediatrics. 1978 Oct. 62(4):492-3. [View Abstract]
  52. Carter SR. Eyelid disorders: diagnosis and management. Am Fam Physician. 1998 Jun. 57(11):2695-702. [View Abstract]
  53. Farpour B, McClellan KA. Diagnosis and management of chronic blepharokeratoconjunctivitis in children. J Pediatr Ophthalmol Strabismus. 2001 Jul-Aug. 38(4):207-12. [View Abstract]
  54. Wald ER. Periorbital and orbital infections. Pediatr Rev. 2004 Sep. 25(9):312-20. [View Abstract]
  55. Yuen SJ, Rubin PA. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophthalmol. 2003 Apr. 121(4):491-9. [View Abstract]
  56. Lamoreau KP, Fanciullo LM. Pott’s Puffy Tumor Mimicking Preseptal Cellulitis. Clin Exp Opt 2007; Published early online. Accessed 15 March, 2008.
  57. Morley AM. Pott's puffy tumour: a rare but sinister cause of periorbital oedema in a child. Eye (Lond). 2009 Apr. 23(4):990-1. [View Abstract]
  58. Swann PG, Weir J. Is it blepharitis?. Clin Exp Optom. 2005 Mar. 88(2):113-4. [View Abstract]
  59. Boruchoff SA, Boruchoff SE. Infections of the lacrimal system. Infect Dis Clin North Am. 1992 Dec. 6(4):925-32. [View Abstract]
  60. Charles NC, Lisman RD, Mittal KR. Carcinoma of the lacrimal canaliculus masquerading as canaliculitis. Arch Ophthalmol. 2006 Mar. 124(3):414-6. [View Abstract]
  61. Howe L, Jones NS. Guidelines for the management of periorbital cellulitis/abscess. Clin Otolaryngol Allied Sci. 2004 Dec. 29(6):725-8. [View Abstract]
  62. Rudloe TF, Harper MB, Prabhu SP, Rahbar R, Vanderveen D, Kimia AA. Acute periorbital infections: who needs emergent imaging?. Pediatrics. 2010 Apr. 125(4):e719-26. [View Abstract]
  63. Cortez O, Schaeffer CJ, Hatem SF, Glauser J, Ahmed M. Cases from the Cleveland Clinic: cerebral venous sinus thrombosis presenting to the emergency department with worst headache of life. Emerg Radiol. 2009 Jan. 16(1):79-82. [View Abstract]
  64. Tost F, Bruder R, Clemens S. Clinical diagnosis of chronic canaliculitis by 20-MHz ultrasound. Ophthalmologica. 2000. 214(6):433-6. [View Abstract]
  65. O'Donnell BA, Clement CI. Assessing patients with epiphora who are patent to syringing: clinical predictors of response to dacryocystorhinostomy. Ophthal Plast Reconstr Surg. 2007 May-Jun. 23(3):173-8. [View Abstract]
  66. Al-Nammari S, Roberton B, Ferguson C. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Should a child with preseptal periorbital cellulitis be treated with intravenous or oral antibiotics?. Emerg Med J. 2007 Feb. 24 (2):128-9. [View Abstract]
  67. American Academy of Pediatrics. Subcommittee on Management of Sinusitis and Committee on Quality Improvement. Clinical practice guideline: management of sinusitis. Pediatrics. 2001 Sep. 108 (3):798-808. [View Abstract]
  68. Vu BL, Dick PT, Levin AV, et al. Development of a clinical severity score for preseptal cellulitis in children. Pediatr Emerg Care. 2003 Oct. 19(5):302-7. [View Abstract]
  69. Thikkurissy S, Rawlins JT, Kumar A, Evans E, Casamassimo PS. Rapid treatment reduces hospitalization for pediatric patients with odontogenic-based cellulitis. Am J Emerg Med. 2010 Jul. 28(6):668-72. [View Abstract]
  70. Upile NS, Munir N, Leong SC, et al. Who should manage acute periorbital cellulitis in children?. Int J Pediatr Otorhinolaryngol. Aug 2012. 76(8):1073-7. [View Abstract]
  71. Viswalingam M, Rauz S, Morlet N, et al. Blepharokeratoconjunctivitis in children: diagnosis and treatment. Br J Ophthalmol. 2005 Apr. 89(4):400-3. [View Abstract]
  72. Yactayo-Miranda Y, Ta CN, He L, Kreutzer TC, Nentwich MM, Kampik A, et al. A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2009 Jul. 247(7):993-8. [View Abstract]
  73. American Academy of Ophthalmology. Preferred Practice Patterns: Blepharitis. Available at: http://one.aao.org. Accessed March 14, 2008.
  74. Belfort R Jr, Gabriel L, Martins Bispo PJ, Muccioli C, Zacharias Serapicos PC, Clark L, et al. Safety and efficacy of moxifloxacin-dexamethasone eyedrops as treatment for bacterial ocular infection associated with bacterial blepharitis. Adv Ther. 2012 May. 29(5):416-26. [View Abstract]
  75. Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008 Sep. 25(9):858-70. [View Abstract]
  76. Bezdetko PA, Sergienko N, Dyomin Y, Korol A, Nikitin N, Merzbacher M, et al. Successful treatment of blepharitis with bibrocathol (Posiformin(®) 2 %). Graefes Arch Clin Exp Ophthalmol. 2012 Apr 25. [View Abstract]
  77. Castanheira M, Watters AA, Bell JM, Turnidge JD, Jones RN. Fusidic Acid Resistance Rates and Prevalence of Resistance Mechanisms Among Staphylococcus spp. isolated in North America and Australia (2007-2008). Antimicrob Agents Chemother. 2010 Jun 21. [View Abstract]
  78. Knezevic T, Ivekovic R, Astalos JP, Novak Laus K, Mandic Z, Matejcic A. Botulinum toxin A injection for primary and recurrent chalazia. Graefes Arch Clin Exp Ophthalmol. 2009 Jun. 247(6):789-94. [View Abstract]
  79. Gao YY, Di Pascuale MA, Elizondo A, Tseng SC. Clinical treatment of ocular demodecosis by lid scrub with tea tree oil. Cornea. 2007 Feb. 26(2):136-43. [View Abstract]
  80. Pinckney J 2nd, Cole P, Vadapalli SP, Rosen T. Phthiriasis palpebrarum: a common culprit with uncommon presentation. Dermatol Online J. 2008. 14(4):7. [View Abstract]
  81. Aburn NS, Sullivan TJ. Infectious mononucleosis presenting with dacryoadenitis. Ophthalmology. 1996 May. 103(5):776-8. [View Abstract]
  82. Greenberg MF, Pollard ZF. The red eye in childhood. Pediatr Clin North Am. 2003 Feb. 50(1):105-24. [View Abstract]
  83. Baylin EB, Gladstone GJ. Endoscopic lacrimal surgery. Otolaryngol Clin North Am. 2005 Oct. 38(5):1099-107. [View Abstract]

Periorbital cellulitis. This image shows an 8-year-old patient who presented with unilateral eyelid swelling and erythema.

Acute dacryocystitis.

Upper eyelid anatomy.

Lower eyelid anatomy.

Eye and lacrimal duct, anterior view.

Periorbital cellulitis. This image shows an 8-year-old patient who presented with unilateral eyelid swelling and erythema.

Acute dacryocystitis.

Periorbital cellulitis. This image shows an 8-year-old patient who presented with unilateral eyelid swelling and erythema.

Acute dacryocystitis.

Upper eyelid anatomy.

Lower eyelid anatomy.

Eye and lacrimal duct, anterior view.